【NEWS】Cyto-Facto Signs Letter of Intent with Steminent for Contract Manufacturing of Stemchymal
2026/01/15
Cyto-Facto Inc. (Headquarters: Kobe, Hyogo, Japan; President & CEO: Yasunori Ishibashi; “Cyto-Facto”) announces that it has entered into a Letter of Intent (“LOI”) with Steminent Biotherapeutics Inc. (Headquarters: Taipei, Taiwan; Chairman & CEO: Ling-Mei Wang; “Steminent”) regarding the contract manufacturing of Steminent’s Mesenchymal stem cell product, Stemchymal.
The LOI was signed on January 14, 2026, in Taipei, in the presence of representatives from both companies.
Under the LOI, Steminent has selected Cyto-Facto as its manufacturing partner for Stemchymal®. The two companies will proceed with detailed discussions toward establishing the manufacturing framework, facility preparations, and future technology transfer for commercial production of Stemchymal. Both parties will continue discussions toward the execution of a definitive contract manufacturing agreement.
Please refer to the press release below for further details.
Cyto-Facto Signs Letter of Intent with Steminent
The LOI was signed on January 14, 2026, in Taipei, in the presence of representatives from both companies.
Under the LOI, Steminent has selected Cyto-Facto as its manufacturing partner for Stemchymal®. The two companies will proceed with detailed discussions toward establishing the manufacturing framework, facility preparations, and future technology transfer for commercial production of Stemchymal. Both parties will continue discussions toward the execution of a definitive contract manufacturing agreement.
Please refer to the press release below for further details.
Cyto-Facto Signs Letter of Intent with Steminent